Ex-Entitlement Date - Unlisted RNV Shares
Roquefort Therapeutics plc announced that its ordinary shares will trade ex-entitlement for Unlisted Redeemable Non-Voting Shares starting December 1, 2025. Holders of ordinary shares and convertible loan notes on the register as of November 28, 2025, are eligible to receive these new shares, as are those who purchased ordinary shares on that date. Further details regarding the entitlement ratio and the exact number of shares to be issued will be provided in a subsequent announcement.
Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that further to the Company's announcement earlier today confirming that the record date for determining entitlement to the Unlisted Redeemable Non-Voting Shares ("Unlisted RNV Shares") has now passed, its ordinary shares will be marked ex-entitlement in respect of the Unlisted RNV Shares with effect from the commencement of trading today, 1 December 2025.
Accordingly, all holders of ordinary shares and convertible loan notes who were on the Company's register as at close of business on 28 November 2025 will be eligible to receive the Unlisted RNV Shares. In addition, anyone who purchased ordinary shares on Friday, 28 November 2025 will also be eligible to receive the Unlisted RNV Shares.
A detailed timetable for the crediting of the Unlisted RNV Shares to eligible shareholders, together with full details of the entitlement ratio and the exact number of Unlisted RNV Shares to be issued, will be set out in a further announcement to be made in due course.
Regulatory Information
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.